Cyprotex PLC Launch of in vitro h-CLAT Service
November 29 2016 - 2:01AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
29 November 2016
29(th) November 2016
Cyprotex PLC
Launch of in vitro h-CLAT Service for assessing skin
sensitisation
Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research
Organisation (CRO), today announces the launch of h-CLAT (human
Cell Line Activation Test), an in vitro service for determining
skin sensitisation potential. Cyprotex have developed this test in
response to the recently released OECD (Organisation for Economic
Co-operation and Development) test guideline 442E.
The European Union, along with many other countries throughout
the world, have now implemented a complete ban on animal testing
within the cosmetics industry. Furthermore, within the chemical
testing industry, animal testing is now only recommended as a last
resort where no suitable alternatives are available. This change in
legislation has driven the development and validation of in silico
and in vitro methods which are now being introduced to replace the
animal methods. One example of where this has been successful is in
the case of skin sensitisation where the mechanism leading to the
adverse effect has been well characterised. This is defined within
an Adverse Outcome Pathway (AOP) which details the biological
processes leading to the initiation of skin sensitisation.
A number of in vitro tests have now been developed which analyse
the key events within the AOP and determine if a substance is
expected to be a skin sensitiser. These tests include the Direct
Protein Reactivity Assay (DPRA) which identifies if the substance
reacts with proteins (Key Event 1 in the AOP), the KeratinoSens(TM)
assay which determines gene activation within human skin cells (Key
Event 2 in the AOP) and h-CLAT which detects cell surface marker
expression in human immune cells (Key Event 3 in the AOP). Cyprotex
is one of the few companies which can now offer all three of these
in vitro tests.
Cyprotex's Chief Executive Officer, Dr Anthony Baxter, said,
'Cyprotex have specialist expertise in the field of in vitro
skin-based tests, and offer a comprehensive panel of regulatory
tests for assessing skin irritation, skin corrosion, skin
sensitisation, skin absorption and phototoxicity. By introducing
h-CLAT alongside our existing DPRA and KeratinoSens(TM) tests, we
are meeting the needs of our clients within the cosmetics, personal
care and chemical industries for non-animal in vitro alternatives
according to current recommended practices for skin sensitisation
testing.'
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1500 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemPK(TM),
chemTarget, chemTox and DDI-Fusion, and a range of skin, ocular and
endocrine disruption services. For more information, please visit
www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADVLFLQFFBFBB
(END) Dow Jones Newswires
November 29, 2016 02:01 ET (07:01 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024